Cart
sales@molnova.com
p38α inhibitor 3
CAS No. 260428-69-1
p38α inhibitor 3( —— )
Catalog No. M36011 CAS No. 260428-69-1
p38α inhibitor 3 is a inhibitor of the mitogen-activated protein kinase p38α that can block the effectiveness of myoblast differentiation.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 10MG | 36 | In Stock |
|
| 25MG | 73 | In Stock |
|
| 50MG | 110 | In Stock |
|
| 100MG | 183 | In Stock |
|
| 200MG | 269 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Namep38α inhibitor 3
-
NoteResearch use only, not for human use.
-
Brief Descriptionp38α inhibitor 3 is a inhibitor of the mitogen-activated protein kinase p38α that can block the effectiveness of myoblast differentiation.
-
Descriptionp38α inhibitor 3 (Comp G7) is a p38α inhibitor that blocks the effectiveness of myoblast differentiation.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMAPK/ERK Signaling
-
Targetp38 MAPK
-
Recptorp38 MAPK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number260428-69-1
-
Formula Weight297.37
-
Molecular FormulaC19H20FNO
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 125 mg/mL (420.35 mM; Ultrasonic )
-
SMILESFc1ccc(cc1)C(=O)N1CCC(Cc2ccccc2)CC1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Yael Friedmann, et al. JX401, A p38alpha inhibitor containing a 4-benzylpiperidine motif, identified via a novel screening system in yeast. Mol Pharmacol. 2006 Oct;70(4):1395-405.??
molnova catalog
related products
-
TAK-715
A potent, selective, orally active p38α MAPK inhibitor with IC50 of 7.1 nM.
-
CC-99677
CC-99677 (Gamcemetinib) is a selectively targeted covalent MAPKAPK2 (MK2) inhibitor for autoimmune diseases that translates biochemical potency into cellular potency as demonstrated by potent inhibition of heat shock protein 27 (HSP1) phosphorylation in LPS-activated monocyte THP-27 cells via a nucleophilic aromatic substitution (SNAr) mechanism.
-
Zunsemetinib
Zunsemetinib (ATI-450) is an orally active and selective inhibitor of the p38α mitogen-activated protein kinase-activated protein kinase 2 (MK2) pathway.
